Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against XBiotech Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. (“XBiotech” or “the Company”) (NASDAQ: XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether XBiotech has violated federal securities laws.
Investigation Details
On December 23, 2024, XBiotech announced that it was pausing the phase 2 rheumatoid arthritis program for its drug candidate, Natrunix. According to the company, the program was paused due to its failure to meet the primary endpoint, and it suffered from “substantial irregularities that make unequivocal interpretation of the findings difficult.” Following this news, XBiotech stock dropped, damaging investors.
What’s Next?
If you are aware of any facts relating to this investigation or purchased XBiotech securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
XBIT — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”